AbbVie Declares Quarterly Dividend
On June 17, 2020, AbbVie (NYSE: ABBV) declared a quarterly cash dividend of $1.18 per share, payable on August 14, 2020 to stockholders of record as of July 15, 2020. Since its inception in 2013, AbbVie has increased its dividend by 195 percent. The company is a member of the S&P Dividend Aristocrats Index, recognizing firms that have raised dividends for at least 25 consecutive years. AbbVie's mission focuses on innovative medicines across various therapeutic areas, including immunology and oncology.
- Declared a quarterly cash dividend of $1.18 per share.
- Dividend increased by 195% since 2013.
- Member of the S&P Dividend Aristocrats Index.
- None.
NORTH CHICAGO, Ill., June 17, 2020 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of
The cash dividend is payable August 14, 2020 to stockholders of record at the close of business on July 15, 2020.
Since the company's inception in 2013, AbbVie has increased its dividend by 195 percent. AbbVie is a member of the S&P Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years.
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook, LinkedIn or -1%26h%3D4214140862%26u%3Dhttp%253A%252F%252Fwww.instagram.com%252Fabbvie%26a%3DInstagram&a=Instagram" rel="nofollow">Instagram.
View original content:http://www.prnewswire.com/news-releases/abbvie-declares-quarterly-dividend-301078807.html
SOURCE AbbVie